Lyell Immunopharma Inc
LYEL
Get informed when a big investor buys or sells
+ FollowMarket Cap$360.46M
Close$
$0.50
96.4% downside
Current Fair Value
96.4% downsideOvervalued by 96.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $360.46 Million |
|---|---|
| Enterprise Value | $324.41 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-16.06 |
| Beta | -0.06 |
| Outstanding Shares | 23,364,000 |
Return
| Return on Equity | -106.27% |
|---|---|
| Return on Assets | -79.86% |
| Return on Invested Capital | 49.59% |
Valuation & Multiples
| P/E Ratio | -0.92 |
|---|---|
| PEG | -18.94 |
| Price to Sales | - |
| Price to Book Ratio | 1.42 |
| Enterprise Value to Revenue | 12015.12 |
| Enterprise Value to EBIT | 2.41 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-2.02
Average shareholder expectationRevenue Estimate
$4,600
Average shareholder expectationNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$-2.03
Average shareholder expectationRevenue Estimate
$4,600
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3425▲ 34.25% |
|---|---|
| Total Calls | 12,000▲ Infinity% |
| Total Puts | 4,110▼ 85.43% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 54.74%▼ 11.99% |
|---|---|
| Total Invested | $237.23M▼ 32.28% |
| Investors Holding | 76▲ 6.00% |
ESG Score
No data
About Lyell Immunopharma Inc
189 employees